Virtual clinical trial simulations for a novel KRASG12C inhibitor (ASP2453) in non‐small cell lung cancer
Abstract KRAS is a small GTPase family protein that relays extracellular growth signals to cell nucleus. KRASG12C mutations lead to constitutive proliferation signaling and are prevalent across human cancers. ASP2453 is a novel, highly potent, and selective inhibitor of KRASG12C. Although preclinica...
Guardado en:
Autores principales: | Hiroyuki Sayama, Diana Marcantonio, Takeyuki Nagashima, Masashi Shimazaki, Tsuyoshi Minematsu, Joshua F Apgar, John M. Burke, Lucia Wille, Yasuhisa Nagasaka, Daniel C. Kirouac |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/307d52ab94554a9cbf4a9e35c1594f22 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Spotlight on Sotorasib (AMG 510) for KRASG12C Positive Non-Small Cell Lung Cancer
por: Zhang S, et al.
Publicado: (2021) -
Porcine pancreatic ductal epithelial cells transformed with KRASG12D and SV40T are tumorigenic
por: Katie L. Bailey, et al.
Publicado: (2021) -
Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation
por: Shaima’a Hamarsheh, et al.
Publicado: (2020) -
Comment on “Correlation of L-asp Activity, Anti-L-asp Antibody, asn and gln with Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL”
por: Wing H. Tong MD, PhD, MSc
Publicado: (2021) -
Author Response: Correlation of L-asp Activity, Anti-L-asp Antibody, Asn and Gln with Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL Patients
por: Shunguo Zhang MB
Publicado: (2021)